Actively Recruiting
Open-Label Study Evaluating Safety and Effects of Marstacimab Following Emicizumab Discontinuation in Males with Severe Hemophilia A
Led by Pfizer · Updated on 2026-10-15
15
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, how the body processes, and how marstacimab works in males aged 12 to less than 75 years with severe hemophilia A without inhibitors. Hemophilia A is a rare bleeding disorder where blood does not clot normally, leading to excessive bleeding. Participants currently on emicizumab treatment for at least 6 months who wish to switch to marstacimab are sought for this non-randomized open-label phase 1b study. Participants will receive marstacimab as weekly subcutaneous injections of 150 mg for a 4-month treatment period, starting no sooner than 14 days after their last emicizumab dose. The study can last up to 6 months, including a minimum 14-day wash-out period after stopping emicizumab before marstacimab begins. After completing marstacimab treatment, participants resume their usual prophylactic care. An optional extension phase is available for those wishing to continue marstacimab where it is not commercially available. During the study, participants will be monitored for safety through reports of adverse events, serious adverse events, and lab tests including pharmacokinetics and pharmacodynamics. They will continue using their standard factor replacement treatment for breakthrough bleeds. Monitoring will continue for at least 28 days after the last dose of marstacimab. The total participation duration is approximately 6 months, with assessments of blood markers and immune response to the drug to support safety evaluation.
CONDITIONS
Brief Title
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here